I went back and read Immune's filing again form this week. I missed this before:
"Bertilimumab is a first-in-class, human, anti-eotaxin-1 antibody that targets eotaxin-1, a key regulator of inflammation. Phase 2 trials of bertilimumab in bullous pemphigoid,ulcerative colitis, allergic rhinitis and allergic conjunctivitis have been completed, although the ulcerative colitis trial remains blinded."
So the UC results are still blinded which makes no sense. I understand why Immune would want to keep the results secret with the ICO motion still pending, but any prospective purchaser is going to want to see those results before buying Bert- that is a no brainer. Maybe there will be a clause in the offer that if the results are positive, the amount they would pay will increase. And then they will unblind the results after the hearing and prior to an auction.
